Get the Stockscreener App
7.56
1.69%
-0.13
Cybin Inc stock is traded at $7.56, with a volume of 381.71K.
It is down -1.69% in the last 24 hours and down -16.00% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$7.69
Open:
$7.5
24h Volume:
381.71K
Relative Volume:
1.06
Market Cap:
$178.34M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-36.40
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-5.38%
1M Performance:
-16.00%
6M Performance:
-23.71%
1Y Performance:
-28.07%
1-Day Range:
$7.3101
$7.69
1-Week Range:
$7.26
$7.985
52-Week Range:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.56 | 177.12M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
How volatile is Cybin Inc. stock compared to the marketWealth Building Guidance For Smart Trading - jammulinksnews.com
What are the latest earnings results for Cybin Inc.Post Market Target Finder To Watch Now - jammulinksnews.com
Cybin Inc. Schedules Virtual Annual General Meeting for August 2025 - MSN
Cybin Inc. May Be Forming Higher Low — Chartwatchers AlertFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
When is Cybin Inc. stock expected to show significant growthMarket Forecast Report For 2025 - jammulinksnews.com
Why is Cybin Inc. stock attracting strong analyst attentionPost Market Trend Scanner For Smart Trading - jammulinksnews.com
Should I hold or sell Cybin Inc. stock in 2025Real Time Insights For 2025 - jammulinksnews.com
What are Cybin Inc. company’s key revenue driversFree Stock Chart Pattern Guide - jammulinksnews.com
What is the dividend policy of Cybin Inc. stockFree Risk Assessment Services - jammulinksnews.com
What are analysts’ price targets for Cybin Inc. in the next 12 monthsInvest confidently with real-time data analysis - jammulinksnews.com
Is Cybin Inc. stock overvalued or undervaluedConsistently superior profits - jammulinksnews.com
What institutional investors are buying Cybin Inc. stockAchieve consistent returns with proven methods - jammulinksnews.com
What are the technical indicators suggesting about Cybin Inc.Access high-yield investment alerts now - jammulinksnews.com
How Cybin Inc. stock performs during market volatilitySolid Return Trade Selections - metal.it
What analysts say about Cybin Inc. stockSuperior portfolio returns - PrintWeekIndia
Cybin Inc. Stock Analysis and ForecastFree Capital Efficiency Planning - PrintWeekIndia
Is Cybin Inc. a good long term investmentExceptional growth trajectory - PrintWeekIndia
Cybin, Inc: CYB003 Vs. GH001Duration, Durability and Protocol Execution - Smartkarma
What drives Cybin Inc. stock pricePowerful market insights - PrintWeekIndia
Will Cybin Inc. stock benefit from AI tech trendsFree Predictions - jammulinksnews.com
I can have 5% loss. - AInvest
(CYBN) Proactive Strategies - news.stocktradersdaily.com
High-Risk, High-Reward Stocks With Serious Momentum: 5 Stocks to Consider - AInvest
Cybin Inc: CYB003 Phase 3 Program Continues to Progress on Plan - Smartkarma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Cap:
|
Volume (24h):